NeuBio
NeuBio is a precision neurobiology company on a mission to improve and extend life for patients with Alzheimer's, Parkinson's, and ALS. They leverage a proprietary bio-analytical platform powered by 'Evolutionary Mathematics' to discover biological factors and novel mRNA biomarkers involved in these neurodegenerative diseases. This advanced AI-driven approach allows for the discovery and validation of biomarkers with unparalleled precision, leading to new precision diagnostics and therapeutic pathways. NeuBio is developing a Next-Gen Sequencing Assay in a CLIA-Certified laboratory and is focused on two key programs: Precision Clinical Trial Screening to improve trial success rates by matching the right patients with the right trials, and Precision Clinical Diagnostics to provide objective, validated, and scalable diagnostic tools. The company has identified 24 potential druggable targets from its biomarker discoveries and is investigating candidate validation through industry partnerships to address the underlying causality of these devastating diseases.
NeuBio
NeuBio is a precision neurobiology company on a mission to improve and extend life for patients with Alzheimer's, Parkinson's, and ALS. They leverage a proprietary bio-analytical platform powered by 'Evolutionary Mathematics' to discover biological factors and novel mRNA biomarkers involved in these neurodegenerative diseases. This advanced AI-driven approach allows for the discovery and validation of biomarkers with unparalleled precision, leading to new precision diagnostics and therapeutic pathways. NeuBio is developing a Next-Gen Sequencing Assay in a CLIA-Certified laboratory and is focused on two key programs: Precision Clinical Trial Screening to improve trial success rates by matching the right patients with the right trials, and Precision Clinical Diagnostics to provide objective, validated, and scalable diagnostic tools. The company has identified 24 potential druggable targets from its biomarker discoveries and is investigating candidate validation through industry partnerships to address the underlying causality of these devastating diseases.